HER-2/neu expression in germ cell tumours
نویسندگان
چکیده
منابع مشابه
Management of ovarian germ cell tumours.
Malignant ovarian germ cell tumours are rare but they occur in women with a mean age of 19 years. It is important that these young patients are not subjected to radical surgery. In most of these patients, they can be cured with either surgery alone and careful surveillance with a combination of clinical examination, computer tomography scanning and serial serum tumour markers. Almost all of tho...
متن کاملPathogenesis of testicular germ cell tumours.
Human germ cell tumours comprise a heterogeneous group of neoplasms. In the testis, three entities are distinguished, the teratomas-yolk sac tumours of the infantile testis, the seminomas and nonseminomas of adolescents and adults, and the spermatocytic seminomas. Studies on epidemiology, histology, clinical behaviour, and chromosomal constitution of these tumours support the concept of distinc...
متن کاملImaging of testicular germ cell tumours
In testicular germ cell tumour (GCT), imaging plays a central role in assessment of tumour bulk, sites of metastases, monitoring response to therapy, surgical planning and accurate assessment of disease at relapse. The primary modality used for imaging patients with GCT is computed tomography (CT) but plain film radiography, ultrasound, magnetic resonance imaging (MRI) and positron emission tom...
متن کاملClinical relevance of HER-2/neu expression in germ-cell testicular tumors.
BACKGROUND Amplification and/or overexpression of HER-2/neu are associated with poor clinical outcome in several epithelial tumors. However, the exact prognostic role of HER-2/neu expression in testicular germ-cell tumors is equivocal. PATIENTS AND METHODS Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed ...
متن کاملL1-CAM is commonly expressed in testicular germ cell tumours.
Germ cell tumors (GCT) are curable cancers, but 10-15% of patients with metastatic disease fail cisplatinbased first-line therapy. While therapeutic options have increased for various other cancers no therapeutic targets have emerged in cisplatin-refractory GCT. L1 cell adhesion molecule (L1-CAM) is commonly expressed in human malignancies and therefore a potential target, however its expressio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Pathology
سال: 2002
ISSN: 0021-9746
DOI: 10.1136/jcp.55.9.656